{"organizations": [], "uuid": "7120201857cb7e99e83e5891420caf77bfe7ce4b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-mylan-to-bring-biosimilar-of-botox/brief-mylan-to-bring-biosimilar-of-botox-to-market-through-collaboration-with-revance-therapeutics-idUSFWN1QI1JE", "country": "US", "domain_rank": 408, "title": "BRIEF-Mylan To Bring Biosimilar Of Botox To Market Through Collaboration With Revance Therapeutics", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-28T23:16:00.000+02:00", "replies_count": 0, "uuid": "7120201857cb7e99e83e5891420caf77bfe7ce4b"}, "author": "", "url": "https://www.reuters.com/article/brief-mylan-to-bring-biosimilar-of-botox/brief-mylan-to-bring-biosimilar-of-botox-to-market-through-collaboration-with-revance-therapeutics-idUSFWN1QI1JE", "ord_in_thread": 0, "title": "BRIEF-Mylan To Bring Biosimilar Of Botox To Market Through Collaboration With Revance Therapeutics", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "revance therapeutics reuters", "sentiment": "none"}, {"name": "mylan nv", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "mylan", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 28, 2018 / 9:16 PM / Updated 8 minutes ago BRIEF-Mylan To Bring Biosimilar Of Botox To Market Through Collaboration With Revance Therapeutics Reuters Staff 1 Min Read Feb 28 (Reuters) - Mylan Nv: * MYLAN TO BRING A BIOSIMILAR OF BOTOX TO THE MARKET THROUGH A COLLABORATION AND LICENSE AGREEMENT WITH REVANCE THERAPEUTICS * MYLAN NV - ‍COLLABORATION AND LICENSE DEAL FOR DEVELOPMENT AND COMMERCIALIZATION OF A PROPOSED BIOSIMILAR TO BOTOX​ * MYLAN NV - ‍COLLABORATION INCLUDES AN UPFRONT PAYMENT OF $25 MILLION TO REVANCE​ * MYLAN TO BRING A BIOSIMILAR OF BOTOX TO THE MARKET THROUGH A COLLABORATION AND LICENSE AGREEMENT WITH REVANCE THERAPEUTICS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-28T23:16:00.000+02:00", "crawled": "2018-02-28T23:30:57.038+02:00", "highlightTitle": ""}